Neurogene (NGNE) Competitors $17.71 +0.27 (+1.55%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$17.81 +0.10 (+0.56%) As of 09/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NGNE vs. NUVB, ORIC, AMLX, MAZE, SION, PHAR, TRVI, ATAI, SPRY, and CRONShould you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Nuvation Bio (NUVB), Oric Pharmaceuticals (ORIC), Amylyx Pharmaceuticals (AMLX), Maze Therapeutics (MAZE), Sionna Therapeutics (SION), Pharming Group (PHAR), Trevi Therapeutics (TRVI), atai Life Sciences (ATAI), ARS Pharmaceuticals (SPRY), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Neurogene vs. Its Competitors Nuvation Bio Oric Pharmaceuticals Amylyx Pharmaceuticals Maze Therapeutics Sionna Therapeutics Pharming Group Trevi Therapeutics atai Life Sciences ARS Pharmaceuticals Cronos Group Nuvation Bio (NYSE:NUVB) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Which has more risk & volatility, NUVB or NGNE? Nuvation Bio has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Do institutionals and insiders hold more shares of NUVB or NGNE? 61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by company insiders. Comparatively, 11.6% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, NUVB or NGNE? Neurogene has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M142.21-$567.94M-$0.63-5.19Neurogene$930K271.74-$75.14M-$4.31-4.11 Do analysts recommend NUVB or NGNE? Nuvation Bio presently has a consensus target price of $7.50, suggesting a potential upside of 129.36%. Neurogene has a consensus target price of $46.17, suggesting a potential upside of 160.68%. Given Neurogene's higher probable upside, analysts clearly believe Neurogene is more favorable than Nuvation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is NUVB or NGNE more profitable? Neurogene has a net margin of 0.00% compared to Nuvation Bio's net margin of -1,413.43%. Neurogene's return on equity of -33.33% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-1,413.43% -46.14% -36.04% Neurogene N/A -33.33%-30.34% Does the media refer more to NUVB or NGNE? In the previous week, Nuvation Bio had 2 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for Nuvation Bio and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.62 beat Nuvation Bio's score of 1.03 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryNeurogene beats Nuvation Bio on 10 of the 17 factors compared between the two stocks. Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NGNE vs. The Competition Export to ExcelMetricNeurogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.90M$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.89%4.62%P/E Ratio-4.1121.0376.6626.52Price / Sales271.74249.07445.5788.86Price / CashN/A45.4837.2260.63Price / Book0.859.5613.946.31Net Income-$75.14M-$53.02M$3.29B$271.37M7 Day Performance-11.80%-1.41%-0.67%0.59%1 Month Performance-13.40%2.98%3.89%6.22%1 Year Performance-57.12%9.49%86.24%28.35% Neurogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NGNENeurogene1.9118 of 5 stars$17.71+1.5%$46.17+160.7%-56.0%$248.90M$930K-4.1190Positive NewsNUVBNuvation Bio2.7108 of 5 stars$3.14flat$7.50+138.9%+6.5%$1.07B$7.87M-4.9860ORICOric Pharmaceuticals4.5353 of 5 stars$10.71-0.6%$17.29+61.4%+4.2%$1.05BN/A-5.6780Positive NewsAMLXAmylyx Pharmaceuticals2.317 of 5 stars$11.85+1.7%$13.25+11.8%+337.3%$1.04B$87.37M-4.74200Analyst ForecastMAZEMaze Therapeutics3.3563 of 5 stars$23.25-0.2%$32.67+40.5%N/A$1.02B$167.50M0.00121Analyst ForecastInsider TradeSIONSionna Therapeutics2.6511 of 5 stars$22.31-2.3%$38.00+70.3%N/A$1.01BN/A0.0035Gap UpPHARPharming Group2.226 of 5 stars$13.72-6.6%$30.00+118.7%+84.6%$1.01B$297.20M-105.50280News CoverageTRVITrevi Therapeutics2.8267 of 5 stars$8.06-2.3%$21.75+169.9%+139.6%$1.00BN/A-19.1920Positive NewsATAIatai Life Sciences3.0975 of 5 stars$4.65+0.4%$11.25+141.9%+260.2%$992.39M$310K-6.7480SPRYARS Pharmaceuticals2.6691 of 5 stars$9.96-0.7%$32.50+226.3%-26.7%$991.23M$89.15M-20.3390Positive NewsCRONCronos Group2.1918 of 5 stars$2.55+0.8%N/A+14.2%$968.72M$117.61M51.00450 Related Companies and Tools Related Companies NUVB Alternatives ORIC Alternatives AMLX Alternatives MAZE Alternatives SION Alternatives PHAR Alternatives TRVI Alternatives ATAI Alternatives SPRY Alternatives CRON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NGNE) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
